HomeCompareLBAI vs ABBV

LBAI vs ABBV: Dividend Comparison 2026

LBAI yields 4.32% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $25.6K in total portfolio value
10 years
LBAI
LBAI
● Live price
4.32%
Share price
$13.43
Annual div
$0.58
5Y div CAGR
30.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$79.1K
Annual income
$19,142.00
Full LBAI calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — LBAI vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLBAIABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LBAI + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LBAI pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LBAI
Annual income on $10K today (after 15% tax)
$367.09/yr
After 10yr DRIP, annual income (after tax)
$16,270.70/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $5,596.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LBAI + ABBV for your $10,000?

LBAI: 50%ABBV: 50%
100% ABBV50/50100% LBAI
Portfolio after 10yr
$91.9K
Annual income
$22,433.86/yr
Blended yield
24.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

LBAI
Analyst Ratings
7
Buy
4
Hold
Consensus: Buy
Price Target
$20.00
+48.9% upside vs current
Range: $20.00 — $20.00
Altman Z
-0.8
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LBAI buys
0
ABBV buys
0
No recent congressional trades found for LBAI or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLBAIABBV
Forward yield4.32%3.12%
Annual dividend / share$0.58$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR30.7%40.6%
Portfolio after 10y$79.1K$104.7K
Annual income after 10y$19,142.00$25,725.73
Total dividends collected$52.1K$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy
Analyst price target$20.00$256.15

Year-by-year: LBAI vs ABBV ($10,000, DRIP)

YearLBAI PortfolioLBAI Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,264$564.45$11,559$438.51$295.00ABBV
2$12,830$776.66$13,494$640.86$664.00ABBV
3$14,808$1,080.50$15,951$945.97$1.1KABBV
4$17,368$1,523.37$19,152$1,413.89$1.8KABBV
5$20,766$2,182.47$23,443$2,146.38$2.7KABBV
6$25,408$3,187.48$29,391$3,321.96$4.0KABBV
7$31,950$4,763.66$37,948$5,265.87$6.0KABBV
8$41,503$7,317.06$50,795$8,596.74$9.3KABBV
9$56,019$11,610.31$71,034$14,549.41$15.0KABBV
10$79,082$19,142.00$104,715$25,725.73$25.6KABBV

LBAI vs ABBV: Complete Analysis 2026

LBAIStock

Lakeland Bancorp, Inc. operates as the bank holding company for Lakeland Bank that offers various banking products and services for individuals and small to medium sized businesses. The company provides commercial banking services, including savings, money market, and time accounts, as well as demand deposits. It is also involved in lending services, including commercial real estate loans, commercial and industrial loans, short and medium term loans, lines of credit, letters of credit, inventory and accounts receivable financing, real estate construction loans, residential mortgage loans, Small Business Administration (SBA) loans, and merchant credit card services; financing solutions to small and medium-sized companies; online banking, mobile banking, and wire transfer services; and cash management services, such as remote capture of deposits and overnight sweep repurchase agreements. In addition, it provides consumer banking services, which include checking accounts, savings accounts, interest-bearing checking accounts, money market accounts, certificates of deposit, online banking, secured and unsecured loans, consumer installment loans, mortgage loans, and safe deposit services. Further, the company offers investment advisory services for individuals and businesses; and securities brokerage services, including mutual funds and variable annuities, as well as commercial title insurance services and life insurance products. As of December 31, 2021, it operated 48 branch offices located throughout Bergen, Essex, Morris, Ocean, Passaic, Somerset, Sussex, and Union counties in New Jersey and in Highland Mills, New York; operated six New Jersey regional commercial lending centers in Bernardsville, Iselin, Jackson, Montville, Teaneck and Waldwick; and one New York commercial lending center to serve the Hudson Valley region. The company was incorporated in 1969 and is headquartered in Oak Ridge, New Jersey.

Full LBAI Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this LBAI vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LBAI vs SCHDLBAI vs JEPILBAI vs OLBAI vs KOLBAI vs MAINLBAI vs JNJLBAI vs MRKLBAI vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.